Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Standard BioTools ( (LAB) ) is now available.
Standard BioTools reported fourth-quarter 2025 revenue from continuing operations of $23.8 million and full-year revenue of $85.3 million, declines of 4% and 6% respectively, driven by weaker consumables and services demand amid funding and capital constraints, partly offset by growth in imaging instruments. Despite an annual net loss of $58.8 million, improved gross margins, lower operating expenses from restructuring, a tax-related swing to fourth-quarter net income, and roughly $550 million in cash and investments following the January 30, 2026 SomaLogic sale leave the company pursuing a path to profitability and inorganic growth, supported by about $1 billion in U.S. NOL carryforwards and a 2026 revenue outlook of $80 million to $85 million from continuing operations.
The most recent analyst rating on (LAB) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.
Spark’s Take on LAB Stock
According to Spark, TipRanks’ AI Analyst, LAB is a Neutral.
The score is held down primarily by weak financial performance (declining revenue, persistent losses, and negative operating/free cash flow) and limited valuation support due to negative earnings and no dividend data. Technical signals are mixed with modest positive MACD but soft recent trend versus short-term moving averages. The major divestiture and resulting cash increase is a meaningful positive offset but does not fully outweigh the current operating challenges.
To see Spark’s full report on LAB stock, click here.
More about Standard BioTools
Standard BioTools Inc., listed on Nasdaq under the ticker LAB, operates in the life sciences tools industry, supplying instruments, consumables and services for applications including imaging, flow and microfluidics. The company focuses on pharmaceutical and research customers, and is positioning a streamlined portfolio with significant net operating loss carryforwards and a strengthened balance sheet to support disciplined M&A-led growth.
Average Trading Volume: 1,651,984
Technical Sentiment Signal: Strong Sell
Current Market Cap: $438.4M
See more data about LAB stock on TipRanks’ Stock Analysis page.